Moderna Cancer Vaccine Scores 'Milestone Victory,' Shares Double, Merck Hits Record High

On Wednesday, Moderna shares surged 100% after its cancer vaccine, developed in partnership with Merck, showed positive results in a late-stage study. The trial, targeting melanoma patients, demonstrated encouraging outcomes. Following this success, Moderna's stock nearly tripled, indicating a significant market reaction to the news. Meanwhile, Merck's shares reached an all-time high. The favorable study results are seen as a "milestone victory" for Moderna and its cancer vaccine development efforts.